Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
The primary objective of this study is to evaluate the efficacy and safety of CDP6038 administered subcutaneous (sc) at various doses compared to placebo.
Rheumatoid Arthritis
BIOLOGICAL: Placebo|BIOLOGICAL: Olokizumab 60 mg|BIOLOGICAL: Olokizumab 120 mg|BIOLOGICAL: Olokizumab 240 mg
Change from Baseline in the Disease Activity Score 28-joint count (C-reactive protein) (DAS28[CRP]) at Week 12, From Week 0 (Baseline) to Week 12
Number of responders in American College of Rheumatology 20% Response Criteria (ACR20) at Week 12, Number of subjects who achieve ACR 20 will be calculated at week 12. The calculation is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards., From Week 0 (Baseline) to Week 12|Number of responders in American College of Rheumatology 50% Response Criteria (ACR50) at Week 12, Number of subjects who achieve ACR 50 will be calculated at week 12. The calculation is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards., From Week 0 (Baseline) to Week 12|Number of responders in American College of Rheumatology 70% Response Criteria (ACR70) at Week 12, Number of subjects who achieve ACR 70 will be calculated at week 12. The calculations is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards., From Week 0 (Baseline) to Week 12
The primary objective of this study is to evaluate the efficacy and safety of CDP6038 administered subcutaneous (sc) at various doses compared to placebo.